
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/">
  <dc:language>eng</dc:language>
  <dc:rights>http://creativecommons.org/licenses/by-nc/4.0/legalcode</dc:rights>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:creator id="https://orcid.org/0000-0001-6027-591X">Sabljić, Ljiljana</dc:creator>
  <dc:creator>Radulović, Nataša</dc:creator>
  <dc:creator>Djokić, Jelena</dc:creator>
  <dc:creator>Stojanović, Dušica B.</dc:creator>
  <dc:creator>Radojević, Dušan</dc:creator>
  <dc:creator id="https://orcid.org/0000-0003-0497-5852">Glamočlija, Sofija</dc:creator>
  <dc:creator>Dinić, Miroslav</dc:creator>
  <dc:creator>Golić, Nataša</dc:creator>
  <dc:creator id="https://orcid.org/0000-0001-7870-2713">Vasilev, Saša</dc:creator>
  <dc:creator>Uskoković, Petar</dc:creator>
  <dc:creator>Sofronić-Milosavljević, Ljiljana</dc:creator>
  <dc:creator id="https://orcid.org/0000-0002-3061-5474">Gruden-Movsesijan, Alisa</dc:creator>
  <dc:creator id="https://orcid.org/0000-0003-2570-1295">Tomić, Sergej</dc:creator>
  <dc:title xml:lang="eng">Biodegradable Electrospun PLGA Nanofibers-Encapsulated Trichinella Spiralis Antigens Protect from Relapsing Experimental Autoimmune Encephalomyelitis and Related Gut Microbiota Dysbiosis</dc:title>
  <dc:publisher>Dovepress Taylor &amp; Francis Group</dc:publisher>
  <dc:format>application/pdf</dc:format>
  <dc:format>15524041 bytes</dc:format>
  <dc:subject xml:lang="eng">electrospinning, PLGA nanofibers, drug delivery, tolerogenic cells, immune modulation, gut microbiota</dc:subject>
  <dc:source>International Journal of Nanomedicine</dc:source>
  <dc:source>volume: 20</dc:source>
  <dc:source>startpage: 1921</dc:source>
  <dc:source>endpage: 1948</dc:source>
  <dc:identifier>https://phaidrabg.bg.ac.rs/o:36023</dc:identifier>
  <dc:identifier>doi:10.2147/IJN.S499161</dc:identifier>
  <dc:date>2025</dc:date>
  <dc:description xml:lang="eng">ABSTRACT
Purpose: Trichinella spiralis has evolved complex immunomodulatory mechanisms mediated by excretory-secretory products (ESL1) that enable its survival in the host. Consequently, ESL1 antigens display excellent potential for treating autoimmune diseases such as multiple sclerosis (MS). However, whether timely controlled delivery of ESL1 antigens in vivo, as in natural infections, could enhance its therapeutic potential for MS is still unknown.
Methods: To test this, we encapsulated ESL1 antigens into biodegradable poly (lactide-co-glycolic) acid (PLGA) nanofibers by emulsion electrospinning as a delivery system and assessed their release dynamics in vitro, and in an animal MS model, experimental autoimmune encephalomyelitis (EAE), induced 7 days after PLGA/ESL1 subcutaneous implantation. PLGA/ESL1 effects on EAE symptoms were monitored along with multiple immune cell subsets in target organs at the peak and recovery of EAE. Gut barrier function and microbiota composition were analyzed using qPCR, 16S rRNA sequencing, and metabolomic analyses.</dc:description>
</oai_dc:dc>
